Andrew Leuchter

Andrew F Leuchter

Professor, Psychiatry and Biobehavioral Sciences, University of California Los Angeles

Publications

  1. Leuchter MK, Citrenbaum C, Wilson AC, Tibbe TD, Jackson NJ, Krantz DE, Wilke SA, Corlier J, Strouse TB, Hoftman GD, Tadayonnejad R, Koek RJ, Slan AR, Ginder ND, Distler MG, Artin H, Lee JH, Adelekun AE, Einstein EH, Oughli HA, Leuchter AF. The effect of older age on outcomes of rTMS treatment for treatment-resistant depression.. International psychogeriatrics, 2024.
  2. Berman ZR, Citrenbaum C, Corlier J, Leuchter AF, Folmer RL, Leuchter MK. Sequential Multilocus Repetitive Transcranial Magnetic Stimulation for Treatment of Tinnitus With and Without Comorbid Major Depressive Disorder.. Neuromodulation : journal of the International Neuromodulation Society, 2024.
  3. Leuchter MK, Citrenbaum C, Wilson AC, Tibbe TD, Jackson NJ, Krantz DE, Wilke SA, Corlier J, Strouse TB, Hoftman GD, Tadayonnejad R, Koek RJ, Slan AR, Ginder ND, Distler MG, Artin H, Lee JH, Adelekun AE, Leuchter AF. A comparison of self- and observer-rated scales for detecting clinical improvement during repetitive transcranial stimulation (rTMS) treatment of depression.. Psychiatry research, 2023.
  4. Einstein EH, Corlier J, Matthews C, Ngo D, Leuchter MK, Citrenbaum C, Vince-Cruz N, Ramesh B, Slan A, Wilke SA, Ginder N, Strouse T, Leuchter AF. Bilateral Cerebellar Repetitive Transcranial Magnetic Stimulation for Chronic Ataxia After Hemorrhagic Stroke: a Case Report.. Cerebellum (London, England), 2023.
  5. Citrenbaum C, Corlier J, Ngo D, Vince-Cruz N, Wilson A, Wilke SA, Krantz D, Tadayonnejad R, Ginder N, Levitt J, Lee JH, Leuchter MK, Strouse TB, Corse A, Vyas P, Leuchter AF. Pretreatment pupillary reactivity is associated with differential early response to 10 Hz and intermittent theta-burst repetitive transcranial magnetic stimulation (rTMS) treatment of major depressive disorder (MDD).. Brain stimulation, 2023.
  6. Tadayonnejad R, Citrenbaum C, Ngo TDP, Corlier J, Wilke SA, Slan A, Distler MG, Hoftman G, Adelekun AE, Leuchter MK, Koek RJ, Ginder ND, Krantz D, Artin H, Strouse T, Bari AA, Leuchter AF. Right lateral orbitofrontal cortex inhibitory transcranial magnetic stimulation for treatment of refractory mood and depression.. Brain stimulation, 2023.
  7. Chu SA, Tadayonnejad R, Corlier J, Wilson AC, Citrenbaum C, Leuchter AF. Rumination symptoms in treatment-resistant major depressive disorder, and outcomes of repetitive Transcranial Magnetic Stimulation (rTMS) treatment.. Translational psychiatry, 2023.
  8. Citrenbaum C, Corlier J, Ngo D, Vince-Cruz N, Wilson A, Wilke S, Krantz D, Tadayonnejad R, Ginder N, Levitt J, Lee JH, Strouse T, Corse A, Vyas P, Leuchter AF. Pretreatment pupillary reactivity is associated with outcome of Repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD).. Journal of affective disorders, 2023.
  9. Yang FC, Zamaria J, Morgan S, Lin E, Leuchter AF, Abrams M, Chang SE, Mischoulon D, Pedrelli P, Fisher L, Nyer M, Yeung A, Jain FA. How family dementia caregivers perceive benefits of a 4-week Mentalizing Imagery Therapy program: a pilot study.. Professional psychology, research and practice, 2022.
  10. Tadayonnejad R, Wilson AC, Chu SA, Corlier J, Citrenbaum C, Ngo TDP, Hovhannisyan E, Ginder ND, Levitt JG, Wilke SA, Krantz D, Bari AA, Leuchter AF. Use of right orbitofrontal repetitive transcranial magnetic stimulation (rTMS) augmentation for treatment-refractory obsessive-compulsive disorder with comorbid major depressive disorder.. Psychiatry research, 2022.
  11. Ahmadi N, Pynoos R, Leuchter A, Kopelowicz A. Reminder-Focused Positive Psychiatry: Suicide Prevention Among Youths With Comorbid Posttraumatic Stress Disorder and Suicidality.. American journal of psychotherapy, 2022.
  12. Marder KG, Cho J, Chincanchan R, Wilson AC, Corlier J, Krantz DE, Ginder ND, Lee JC, Wilke SA, Tadayonnejad R, Levitt J, Ishiyama A, Leuchter MK, Leuchter AF. Sequential Prefrontal and Temporoparietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Tinnitus With and Without Comorbid Depression: A Case Series and Systematic Review.. Frontiers in neurology, 2022.
  13. Wilke SA, Johnson CL, Corlier J, Marder KG, Wilson AC, Pleman CM, Leuchter AF. Psychostimulant use and clinical outcome of repetitive transcranial magnetic stimulation treatment of major depressive disorder.. Depression and anxiety, 2022.
  14. Leuchter MK, Rosenberg BM, Schapira G, Wong NR, Leuchter AF, McGlade AL, Krantz DE, Ginder ND, Lee JC, Wilke SA, Tadayonnejad R, Levitt J, Marder KG, Craske MG, Iacoboni M. Treatment of Spider Phobia Using Repeated Exposures and Adjunctive Repetitive Transcranial Magnetic Stimulation: A Proof-of-Concept Study.. Frontiers in psychiatry, 2022.
  15. Mirman AM, Corlier J, Wilson AC, Tadayonnejad R, Marder KG, Pleman CM, Krantz DE, Wilke SA, Levitt JG, Ginder ND, Ojha R, Daskalakis ZJ, Leuchter AF, Lee JC. Absence of early mood improvement as a robust predictor of rTMS nonresponse in major depressive disorder.. Depression and anxiety, 2022.
  16. Leuchter AF, Wilson AC, Vince-Cruz N, Corlier J. Novel method for identification of individualized resonant frequencies for treatment of Major Depressive Disorder (MDD) using repetitive Transcranial Magnetic Stimulation (rTMS): A proof-of-concept study.. Brain stimulation, 2021.
  17. Wong WW, Rangaprakash D, Larson MS, Diaz-Fong JP, Tadayonnejad R, Leuchter AF, Feusner JD. Can excitatory neuromodulation change distorted perception of one's appearance?. Brain stimulation, 2021.
  18. Lee JC, Corlier J, Wilson AC, Tadayonnejad R, Marder KG, Ngo D, Krantz DE, Wilke SA, Levitt JG, Ginder ND, Leuchter AF. Subthreshold stimulation intensity is associated with greater clinical efficacy of intermittent theta-burst stimulation priming for Major Depressive Disorder.. Brain stimulation, 2021.
  19. Corlier J, Tadayonnejad R, Wilson AC, Lee JC, Marder KG, Ginder ND, Wilke SA, Levitt J, Krantz D, Leuchter AF. Repetitive transcranial magnetic stimulation treatment of major depressive disorder and comorbid chronic pain: response rates and neurophysiologic biomarkers.. Psychological medicine, 2021.
  20. Jain FA, Chernyak S, Nickerson L, Abrams M, Iacoboni M, Christov-Moore L, Connolly CG, Fisher LB, Sakurai H, Bentley K, Tan E, Pittman M, Lavretsky H, Leuchter AF. Mentalizing imagery therapy for depressed family dementia caregivers: Feasibility, clinical outcomes and brain connectivity changes.. Journal of affective disorders reports, 2021.
  21. Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: A systematic review and meta-analysis.. Translational psychiatry, 2021.
  22. Roelofs CL, Krepel N, Corlier J, Carpenter LL, Fitzgerald PB, Daskalakis ZJ, Tendolkar I, Wilson A, Downar J, Bailey NW, Blumberger DM, Vila-Rodriguez F, Leuchter AF, Arns M. Individual alpha frequency proximity associated with repetitive transcranial magnetic stimulation outcome: An independent replication study from the ICON-DB consortium.. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2020.
  23. Bailey NW, Krepel N, van Dijk H, Leuchter AF, Vila-Rodriguez F, Blumberger DM, Downar J, Wilson A, Daskalakis ZJ, Carpenter LL, Corlier J, Arns M, Fitzgerald PB. Resting EEG theta connectivity and alpha power to predict repetitive transcranial magnetic stimulation response in depression: A non-replication from the ICON-DB consortium.. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2020.
  24. Tadayonnejad R, Wilson AC, Corlier J, Lee JC, Ginder ND, Levitt JG, Wilke SA, Marder KG, Krantz D, Bari AA, Feusner JD, Pouratian N, Leuchter AF. Sequential multi-locus transcranial magnetic stimulation for treatment of obsessive-compulsive disorder with comorbid major depression: A case series.. Brain stimulation, 2020.
  25. Lee JC, Wilson AC, Corlier J, Tadayonnejad R, Marder KG, Pleman CM, Krantz DE, Wilke SA, Levitt JG, Ginder ND, Leuchter AF. Strategies for augmentation of high-frequency left-sided repetitive transcranial magnetic stimulation treatment of major depressive disorder.. Journal of affective disorders, 2020.
  26. Zorick T, Landers J, Leuchter A, Mandelkern MA. EEG multifractal analysis correlates with cognitive testing scores and clinical staging in mild cognitive impairment.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020.
  27. Cook IA, Wilson AC, Peters JM, Goyal MN, Bebin EM, Northrup H, Krueger D, Leuchter AF, Sahin M, TACERN Study Group. EEG Spectral Features in Sleep of Autism Spectrum Disorders in Children with Tuberous Sclerosis Complex.. Journal of autism and developmental disorders, 2020.
  28. Cook IA, Hunter AM, Caudill MM, Abrams MJ, Leuchter AF. Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial.. Journal of psychiatric research, 2020.
  29. Hunter AM, Leuchter AF. Benzodiazepine Use and rTMS Outcome.. The American journal of psychiatry, 2020.
  30. Corlier J, Burnette E, Wilson AC, Lou JJ, Landeros A, Minzenberg MJ, Leuchter AF. Effect of repetitive transcranial magnetic stimulation (rTMS) treatment of major depressive disorder (MDD) on cognitive control.. Journal of affective disorders, 2020.
  31. Corlier J, Wilson A, Hunter AM, Vince-Cruz N, Krantz D, Levitt J, Minzenberg MJ, Ginder N, Cook IA, Leuchter AF. Changes in Functional Connectivity Predict Outcome of Repetitive Transcranial Magnetic Stimulation Treatment of Major Depressive Disorder.. Cerebral cortex (New York, N.Y. : 1991), 2019.
  32. Levitt JG, Kalender G, O’Neill J, Diaz JP, Cook IA, Ginder N, Krantz D, Minzenberg MJ, Vince-Cruz N, Nguyen LD, Alger JR, Leuchter AF. Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy. Journal of psychiatry & neuroscience : JPN, 2019.
  33. Cook IA, Congdon E, Krantz DE, Hunter AM, Coppola G, Hamilton SP, Leuchter AF. Time Course of Changes in Peripheral Blood Gene Expression During Medication Treatment for Major Depressive Disorder.. Frontiers in genetics, 2019.
  34. Corlier J, Carpenter LL, Wilson AC, Tirrell E, Gobin AP, Kavanaugh B, Leuchter AF. The relationship between individual alpha peak frequency and clinical outcome with repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder (MDD).. Brain stimulation, 2019.
  35. Davis PE, Kapur K, Filip-Dhima R, Trowbridge SK, Little E, Wilson A, Leuchter A, Bebin EM, Krueger D, Northrup H, Wu JY, Sahin M, Peters JM, Tuberous Sclerosis Autism Centers of Excellence Research Network. Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex.. Epilepsia, 2019.
  36. Jain FA, Connolly CG, Moore LC, Leuchter AF, Abrams M, Ben-Yelles RW, Chang SE, Ramirez Gomez LA, Huey N, Lavretsky H, Iacoboni M. Grief, Mindfulness and Neural Predictors of Improvement in Family Dementia Caregivers.. Frontiers in human neuroscience, 2019.
  37. Minzenberg MJ, Leuchter AF. The effect of psychotropic drugs on cortical excitability and plasticity measured with transcranial magnetic stimulation: Implications for psychiatric treatment.. Journal of affective disorders, 2019.
  38. Hunter AM, Minzenberg MJ, Cook IA, Krantz DE, Levitt JG, Rotstein NM, Chawla SA, Leuchter AF. Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder.. Brain and behavior, 2019.
  39. McGough JJ, Sturm A, Cowen J, Tung K, Salgari GC, Leuchter AF, Cook IA, Sugar CA, Loo SK. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder.. Journal of the American Academy of Child and Adolescent Psychiatry, 2019.
  40. Cook IA, Wilson AC, Corlier J, Leuchter AF. Brain Activity and Clinical Outcomes in Adults With Depression Treated With Synchronized Transcranial Magnetic Stimulation: An Exploratory Study.. Neuromodulation : journal of the International Neuromodulation Society, 2019.
  41. Voigt J, Carpenter L, Leuchter A. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder.. BMC psychiatry, 2019.
  42. Philip NS, Leuchter AF, Cook IA, Massaro J, Goethe JW, Carpenter LL. Predictors of response to synchronized transcranial magnetic stimulation for major depressive disorder.. Depression and anxiety, 2018.
  43. Leuchter AF, Corlier J. A precision medicine approach to repetitive Transcranial Magnetic Stimulation (rTMS).. Brain stimulation, 2018.
  44. Hunter AM, Nghiem TX, Cook IA, Krantz DE, Minzenberg MJ, Leuchter AF. Change in Quantitative EEG Theta Cordance as a Potential Predictor of Repetitive Transcranial Magnetic Stimulation Clinical Outcome in Major Depressive Disorder.. Clinical EEG and neuroscience, 2017.
  45. Voigt J, Carpenter L, Leuchter A. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis.. PloS one, 2017.
  46. Van Dyk K, Hunter AM, Ercoli L, Petersen L, Leuchter AF, Ganz PA. Evaluating cognitive complaints in breast cancer survivors with the FACT-Cog and quantitative electroencephalography.. Breast cancer research and treatment, 2017.
  47. Fogelson DL, Leuchter A. Defining Treatment-Resistant Depression.. JAMA psychiatry, 2017.
  48. Kobayashi B, Cook IA, Hunter AM, Minzenberg MJ, Krantz DE, Leuchter AF. Can neurophysiologic measures serve as biomarkers for the efficacy of repetitive transcranial magnetic stimulation treatment of major depressive disorder?. International review of psychiatry (Abingdon, England), 2017.
  49. Leuchter MK, Donzis EJ, Cepeda C, Hunter AM, Estrada-Sánchez AM, Cook IA, Levine MS, Leuchter AF. Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?. Frontiers in neurology, 2017.
  50. Leuchter AF, Hunter AM, Jain FA, Tartter M, Crump C, Cook IA. Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder.. Journal of psychiatric research, 2016.
  51. Scanlon GC, Jain FA, Hunter AM, Cook IA, Leuchter AF. Neurophysiologic Correlates of Headache Pain in Subjects With Major Depressive Disorder.. Clinical EEG and neuroscience, 2016.
  52. Koek RJ, Schwartz HN, Scully S, Langevin JP, Spangler S, Korotinsky A, Jou K, Leuchter A. Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future.. Progress in neuro-psychopharmacology & biological psychiatry, 2016.
  53. Cook IA, Abrams M, Leuchter AF. Trigeminal Nerve Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder.. Neuromodulation : journal of the International Neuromodulation Society, 2016.
  54. Leuchter AF, Hunter AM, Tartter M, Cook IA. Authors' reply.. The British journal of psychiatry : the journal of mental science, 2015.
  55. Hunter AM, Cook IA, Tartter M, Sharma SK, Disse GD, Leuchter AF. Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder.. Psychopharmacology, 2015.
  56. Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.. Brain stimulation, 2015.
  57. Leuchter AF, Hunter AM, Tartter M, Cook IA. Author's reply: To PMID 25213159.. The British journal of psychiatry : the journal of mental science, 2015.
  58. Leuchter AF, Hunter AM, Krantz DE, Cook IA. Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments.. Annals of the New York Academy of Sciences, 2015.
  59. Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial.. Psycho-oncology, 2015.
  60. Jain FA, Hunter AM, Leuchter AF, Brooks JO. A role for profiles of patient-specific depression characteristics and socioeconomic factors in the prediction of antidepressant treatment outcome.. The Journal of clinical psychiatry, 2015.
  61. Leuchter AF, Hunter AM, Krantz DE, Cook IA. Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder.. Dialogues in clinical neuroscience, 2014.
  62. McGough JJ, Loo SK, Sturm A, Cowen J, Leuchter AF, Cook IA. An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder.. Brain stimulation, 2014.
  63. Caudill MM, Hunter AM, Cook IA, Leuchter AF. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.. Clinical EEG and neuroscience, 2014.
  64. Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression.. The British journal of psychiatry : the journal of mental science, 2014.
  65. Jain FA, Cook IA, Leuchter AF, Hunter AM, Davydov DM, Ottaviani C, Tartter M, Crump C, Shapiro D. Heart rate variability and treatment outcome in major depression: a pilot study.. International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2014.
  66. Leuchter AF, McGough JJ, Korb AS, Hunter AM, Glaser PE, Deldar A, Durell TM, Cook IA. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.. Journal of psychiatric research, 2014.
  67. Cook IA, Hunter AM, Korb AS, Leuchter AF. Do prefrontal midline electrodes provide unique neurophysiologic information in Major Depressive Disorder?. Journal of psychiatric research, 2014.
  68. Hunter AM, Kwan L, Ercoli LM, Mills BK, Cook IA, Ganz PA, Leuchter AF. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study.. Psycho-oncology, 2014.
  69. Cook IA, Espinoza R, Leuchter AF. Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation).. Neurosurgery clinics of North America, 2014.
  70. Ercoli LM, Castellon SA, Hunter AM, Kwan L, Kahn-Mills BA, Cernin PA, Leuchter AF, Ganz PA. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints.. Brain imaging and behavior, 2013.
  71. Hunter AM, Cook IA, Abrams M, Leuchter AF. Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes?. Medical hypotheses, 2013.
  72. Cook IA, Schrader LM, Degiorgio CM, Miller PR, Maremont ER, Leuchter AF. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study.. Epilepsy & behavior : E&B, 2013.
  73. Hunter AM, Leuchter AF, Power RA, Muthén B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, Hamilton SP. A genome-wide association study of a sustained pattern of antidepressant response.. Journal of psychiatric research, 2013.
  74. Leuchter AF, Cook IA, Jin Y, Phillips B. The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder.. Frontiers in human neuroscience, 2013.
  75. Leuchter A, Simon SL, Daly KA, Rosenberg-Thompson S, Abrams M, Dunkin JJ, Cook IA, Newton TF, Walter DO, Cummings JL. Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2013.
  76. Leuchter A, Simon SL, Daly KA, Abrams M, Rosenberg-Thompson S, Dunkin JJ, Cook IA, Newton TF, Spar JE. Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part II: Two-Year Follow-Up of Patients With Depression.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2013.
  77. Jain FA, Hunter AM, Brooks JO, Leuchter AF. Predictive socioeconomic and clinical profiles of antidepressant response and remission.. Depression and anxiety, 2013.
  78. Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.. The Journal of clinical psychiatry, 2013.
  79. Hunter AM, Korb AS, Cook IA, Leuchter AF. Rostral anterior cingulate activity in major depressive disorder: state or trait marker of responsiveness to medication?. The Journal of neuropsychiatry and clinical neurosciences, 2013.
  80. Leuchter A, Cook IA, Hunter AM. Comment on 'The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants'.. Journal of psychopharmacology (Oxford, England), 2012.
  81. Hunter AM, Cook IA, Leuchter AF. Does prior antidepressant treatment of major depression impact brain function during current treatment?. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012.
  82. Leuchter AF, Cook IA, Hunter AM, Cai C, Horvath S. Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depression.. PloS one, 2012.
  83. Kerber KB, Wisniewski SR, Luther JF, Leuchter AF, D'Empaire I, Trivedi MH, Rush AJ. Effects of heart disease on depression treatment: results from the COMED study.. General hospital psychiatry, 2011.
  84. Hunter AM, Cook IA, Greenwald SD, Tran ML, Miyamoto KN, Leuchter AF. The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 2011.
  85. Korb AS, Hunter AM, Cook IA, Leuchter AF. Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.. Psychiatry research, 2011.
  86. Muthén B, Asparouhov T, Hunter AM, Leuchter AF. Growth modeling with nonignorable dropout: alternative analyses of the STAR*D antidepressant trial.. Psychological methods, 2011.
  87. Rabinoff M, Kitchen CM, Cook IA, Leuchter AF. Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment.. The open medical informatics journal, 2011.
  88. Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM, Faull K, Whitelegge J, Andrews AM, Loo J, Way B, Nelson SF, Horvath S, Lebowitz BD. Biomarkers to predict antidepressant response.. Current psychiatry reports, 2010.
  89. Hunter AM, Leuchter AF, Cook IA, Abrams M. Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.. Acta psychiatrica Scandinavica, 2010.
  90. Hunter AM, Cook IA, Leuchter AF. Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression.. Journal of clinical psychopharmacology, 2010.
  91. Hunter A, Bordelon Y, Cook I, Leuchter A. QEEG Measures in Huntington's Disease: A Pilot Study.. PLoS currents, 2010.
  92. Warden D, Trivedi MH, Wisniewski SR, Kurian B, Zisook S, Kornstein SG, Friedman ES, Miyahara S, Leuchter AF, Fava M, Rush AJ. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.. Journal of clinical psychopharmacology, 2010.
  93. Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JB, Cook IA, Leon AC, Alpert J. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.. Journal of clinical psychopharmacology, 2010.
  94. Farahbod H, Cook IA, Korb AS, Hunter AM, Leuchter AF. Amygdala lateralization at rest and during viewing of neutral faces in major depressive disorder using low-resolution brain electromagnetic tomography.. Clinical EEG and neuroscience, 2010.
  95. Cook IA, Hunter AM, Abrams M, Siegman B, Leuchter AF. Midline and right frontal brain function as a physiologic biomarker of remission in major depression.. Psychiatry research, 2009.
  96. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.. Psychiatry research, 2009.
  97. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.. Psychiatry research, 2009.
  98. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder.. Journal of clinical psychopharmacology, 2009.
  99. Hunter AM, Muthén BO, Cook IA, Leuchter AF. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.. Journal of psychiatric research, 2009.
  100. Korb AS, Hunter AM, Cook IA, Leuchter AF. Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression.. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2009.
  101. Leuchter AF, Husain MM, Cook IA, Trivedi MH, Wisniewski SR, Gilmer WS, Luther JF, Fava M, Rush AJ. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.. Psychological medicine, 2009.
  102. Hunter AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS. Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.. Pain medicine (Malden, Mass.), 2009.
  103. Leuchter AF, Cook IA, Hunter A, Korb A. Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.. Clinical EEG and neuroscience, 2009.
  104. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response.. Dialogues in clinical neuroscience, 2009.
  105. Kalechstein AD, De la Garza R, Newton TF, Green MF, Cook IA, Leuchter AF. Quantitative EEG abnormalities are associated with memory impairment in recently abstinent methamphetamine-dependent individuals.. The Journal of neuropsychiatry and clinical neurosciences, 2009.
  106. Hunter AM, Ravikumar S, Cook IA, Leuchter AF. Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.. Acta psychiatrica Scandinavica, 2008.
  107. Korb AS, Cook IA, Hunter AM, Leuchter AF. Brain electrical source differences between depressed subjects and healthy controls.. Brain topography, 2008.
  108. Leuchter AF, Cook IA, DeBrota DJ, Hunter AM, Potter WZ, McGrouther CC, Morgan ML, Abrams M, Siegman B. Changes in brain function during administration of venlafaxine or placebo to normal subjects.. Clinical EEG and neuroscience, 2008.
  109. Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M, Gaynes BN, Stewart JW. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.. Journal of psychiatric practice, 2008.
  110. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.. The American journal of psychiatry, 2008.
  111. Shapiro D, Cook IA, Davydov DM, Ottaviani C, Leuchter AF, Abrams M. Yoga as a complementary treatment of depression: effects of traits and moods on treatment outcome.. Evidence-based complementary and alternative medicine : eCAM, 2007.
  112. Leuchter A, Levey GS. Need to strike balance with industry-academia rules.. Nature, 2007.
  113. Cook IA, Bookheimer SY, Mickes L, Leuchter AF, Kumar A. Aging and brain activation with working memory tasks: an fMRI study of connectivity.. International journal of geriatric psychiatry, 2007.
  114. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski SR, Balasubramani GK, Fava M, Rush AJ. Insured and non-insured depressed outpatients: how do they compare?. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2007.
  115. Hunter AM, Cook IA, Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder.. The Psychiatric clinics of North America, 2007.
  116. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.. The American journal of psychiatry, 2006.
  117. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Neurophysiologic changes during estrogen augmentation in perimenopausal depression.. Maturitas, 2006.
  118. Claassen CA, Trivedi MH, Rush AJ, Husain MM, Zisook S, Young E, Leuchter A, Wisniewski SR, Balasubramani GK, Alpert J. Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial.. Journal of affective disorders, 2006.
  119. Moses T, Leuchter AF, Cook I, Abrams M. Does the clinical course of depression determine improvement in symptoms and quality of life?. The Journal of nervous and mental disease, 2006.
  120. Venneman S, Leuchter A, Bartzokis G, Beckson M, Simon SL, Schaefer M, Rawson R, Newton T, Cook IA, Uijtdehaage S, Ling W. Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition.. The Journal of neuropsychiatry and clinical neurosciences, 2006.
  121. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study.. Journal of psychiatric research, 2005.
  122. Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain.. Psychosomatics, 2005.
  123. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski SR, Balasubramani GK, Petersen T, Stegman D, Rush AJ. Characteristics of insured and noninsured outpatients with depression in STAR(*)D.. Psychiatric services (Washington, D.C.), 2005.
  124. Morgan ML, Witte EA, Cook IA, Leuchter AF, Abrams M, Siegman B. Influence of age, gender, health status, and depression on quantitative EEG.. Neuropsychobiology, 2005.
  125. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study.. The Journal of clinical psychiatry, 2005.
  126. Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005.
  127. Stubbeman WF, Leuchter AF, Cook IA, Shurman BD, Morgan M, Gunay I, Gonzalez S. Pretreatment neurophysiologic function and ECT response in depression.. The journal of ECT, 2004.
  128. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M. Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.. The Journal of clinical psychiatry, 2004.
  129. Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.. Psychopharmacology, 2004.
  130. Marie-Mitchell A, Leuchter AF, Chou CP, James Gauderman W, Azen SP. Predictors of improved mood over time in clinical trials for major depression.. Psychiatry research, 2004.
  131. Cook IA, Leuchter AF, Morgan ML, Dunkin JJ, Witte E, David S, Mickes L, O'Hara R, Simon S, Lufkin R, Abrams M, Rosenberg S. Longitudinal progression of subclinical structural brain disease in normal aging.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2004.
  132. Newton TF, Kalechstein AD, Hardy DJ, Cook IA, Nestor L, Ling W, Leuchter AF. Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers.. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2004.
  133. Newton TF, Cook IA, Kalechstein AD, Duran S, Monroy F, Ling W, Leuchter AF. Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals.. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2003.
  134. Cook IA, Morgan ML, Dunkin JJ, David S, Witte E, Lufkin R, Abrams M, Rosenberg S, Leuchter AF. Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study.. International journal of geriatric psychiatry, 2002.
  135. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo.. The American journal of psychiatry, 2002.
  136. Cook IA, Leuchter AF. Prefrontal changes and treatment response prediction in depression.. Seminars in clinical neuropsychiatry, 2001.
  137. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S. Executive dysfunction predicts nonresponse to fluoxetine in major depression.. Journal of affective disorders, 2000.
  138. Edwards-Lee T, Cook I, Fairbanks L, Leuchter A, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer disease.. Neuropsychiatry, neuropsychology, and behavioral neurology, 2000.
  139. Holschneider DP, Leuchter AF. Attenuation of brain high frequency electrocortical response after thiopental in early stages of Alzheimer's dementia.. Psychopharmacology, 2000.
  140. Holschneider DP, Waite JJ, Leuchter AF, Walton NY, Scremin OU. Changes in electrocortical power and coherence in response to the selective cholinergic immunotoxin 192 IgG-saporin.. Experimental brain research, 1999.
  141. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects.. Psychiatry research, 1999.
  142. Cook IA, Leuchter AF, Witte E, Abrams M, Uijtdehaage SH, Stubbeman W, Rosenberg-Thompson S, Anderson-Hanley C, Dunkin JJ. Neurophysiologic predictors of treatment response to fluoxetine in major depression.. Psychiatry research, 1999.
  143. Bystritsky A, Leuchter AF, Vapnik T. EEG abnormalities in nonmedicated panic disorder.. The Journal of nervous and mental disease, 1999.
  144. Holschneider DP, Leuchter AF. Clinical neurophysiology using electroencephalography in geriatric psychiatry: neurobiologic implications and clinical utility.. Journal of geriatric psychiatry and neurology, 1999.
  145. Cook IA, O'Hara R, Uijtdehaage SH, Mandelkern M, Leuchter AF. Assessing the accuracy of topographic EEG mapping for determining local brain function.. Electroencephalography and clinical neurophysiology, 1998.
  146. Cook IA, Leuchter AF, Uijtdehaage SH, Osato S, Holschneider DH, Abrams M, Rosenberg-Thompson S. Altered cerebral energy utilization in late life depression.. Journal of affective disorders, 1998.
  147. Holschneider DP, Leuchter AF, Scremin OU, Treiman DM, Walton NY. Effects of cholinergic deafferentation and NGF on brain electrical coherence.. Brain research bulletin, 1998.
  148. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM. Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions.. Brain research, 1997.
  149. Holschneider DP, Leuchter AF, Uijtdehaage SH, Abrams M, Rosenberg-Thompson S. Loss of high-frequency brain electrical response to thiopental administration in Alzheimer's-type dementia.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1997.
  150. Leuchter AF, Cook IA, Uijtdehaage SH, Dunkin J, Lufkin RB, Anderson-Hanley C, Abrams M, Rosenberg-Thompson S, O'Hara R, Simon SL, Osato S, Babaie A. Brain structure and function and the outcomes of treatment for depression.. The Journal of clinical psychiatry, 1997.
  151. Newton TF, Leuchter AF, van Gorp WG, Hinkin CH, Mandelkern M, Weiner H. EEG power correlates with subcortical metabolic activity in AIDS.. The Journal of neuropsychiatry and clinical neurosciences, 1997.
  152. Cook IA, Leuchter AF. Synaptic dysfunction in Alzheimer's disease: clinical assessment using quantitative EEG.. Behavioural brain research, 1996.
  153. Yener GG, Leuchter AF, Jenden D, Read SL, Cummings JL, Miller BL. Quantitative EEG in frontotemporal dementia.. Clinical EEG (electroencephalography), 1996.
  154. Holschneider DP, Leuchter AF. Beta activity in aging and dementia.. Brain topography, 1995.
  155. Dunkin JJ, Osato S, Leuchter AF. Relationships between EEG coherence and neuropsychological tests in dementia.. Clinical EEG (electroencephalography), 1995.
  156. Leuchter AF, Dunkin JJ, Lufkin RB, Anzai Y, Cook IA, Newton TF. Effect of white matter disease on functional connections in the aging brain.. Journal of neurology, neurosurgery, and psychiatry, 1994.
  157. Newton TF, Leuchter AF, Walter DO, van Gorp WG, Morgenstern H, Miller EN, Lieb K, Visscher B, Satz P, Weiner H. Electroencephalographic coherence in acquired immune deficiency syndrome.. Psychiatry research, 1994.
  158. Leuchter AF, Cook IA, Mena I, Dunkin JJ, Cummings JL, Newton TF, Migneco O, Lufkin RB, Walter DO, Lachenbruch PA. Assessment of cerebral perfusion using quantitative EEG cordance.. Psychiatry research, 1994.
  159. Leuchter AF, Cook IA, Lufkin RB, Dunkin J, Newton TF, Cummings JL, Mackey JK, Walter DO. Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography.. NeuroImage, 1994.
  160. Dunkin JJ, Leuchter AF, Newton TF, Cook IA. Reduced EEG coherence in dementia: state or trait marker?. Biological psychiatry, 1994.
  161. Newton TF, Leuchter AF, Miller EN, Weiner H. Quantitative EEG in patients with AIDS and asymptomatic HIV infection.. Clinical EEG (electroencephalography), 1994.
  162. Leuchter AF, Cook IA, Newton TF, Dunkin J, Walter DO, Rosenberg-Thompson S, Lachenbruch PA, Weiner H. Regional differences in brain electrical activity in dementia: use of spectral power and spectral ratio measures.. Electroencephalography and clinical neurophysiology, 1993.
  163. Jacobson SA, Leuchter AF, Walter DO, Weiner H. Serial quantitative EEG among elderly subjects with delirium.. Biological psychiatry, 1993.
  164. Leuchter AF, Daly KA, Rosenberg-Thompson S, Abrams M. Prevalence and significance of electroencephalographic abnormalities in patients with suspected organic mental syndromes.. Journal of the American Geriatrics Society, 1993.
  165. Small GW, Leuchter AF, Mandelkern MA, La Rue A, Okonek A, Lufkin RB, Jarvik LF, Matsuyama SS, Bondareff W. Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type.. Archives of neurology, 1993.
  166. Jacobson SA, Leuchter AF, Walter DO. Conventional and quantitative EEG in the diagnosis of delirium among the elderly.. Journal of neurology, neurosurgery, and psychiatry, 1993.
  167. Newton TF, Leuchter AF, Walter DO, Van Gorp WC, Stern CE, Mandelkern M, Weiner H. EEG coherence in men with AIDS: association with subcortical metabolic activity.. The Journal of neuropsychiatry and clinical neurosciences, 1993.
  168. Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA. Changes in brain functional connectivity in Alzheimer-type and multi-infarct dementia.. Brain : a journal of neurology, 1992.
  169. Szuba MP, Leuchter AF. Falling backward in two elderly patients taking bupropion.. The Journal of clinical psychiatry, 1992.
  170. Leuchter AF, Read SL, Shapira J, Walter DO, Smith C. Stable bimodal response to cholinomimetic drugs in Alzheimer's disease. Brain mapping correlates.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1991.
  171. Leuchter AF, Jacobson SA. Quantitative measurement of brain electrical activity in delirium.. International psychogeriatrics, 1991.
  172. Leuchter AF, Walter DO. Diagnosis and assessment of dementia using functional brain imaging.. International psychogeriatrics, 1989.
  173. Leuchter AF, Spar JE, Walter DO, Weiner H. Electroencephalographic spectra and coherence in the diagnosis of Alzheimer's-type and multi-infarct dementia. A pilot study.. Archives of general psychiatry, 1987.
  174. Leuchter AF, Spar JE. The late-onset psychoses. Clinical and diagnostic features.. The Journal of nervous and mental disease, 1985.